Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 5 of 5 results for pentoxifylline

  1. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

    Technology appraisal guidance
    Published
    25 May 2011
    View recommendations

    Sections for TA223

  2. A trial comparing the long-term effectiveness (beyond 24 weeks) of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate and placebo would be beneficial. It should collect utility data as well as walking distance outcomes.

    effectiveness (beyond 24 weeks) of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate and placebo would be...

    Research recommendation
    Published
    9 June 2015

  3. LQD Spray for treating acute and chronic wounds (MIB202)

    NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .

    Medtech innovation briefing
    Published
    17 December 2019

  4. Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)

    NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease

    Medtech innovation briefing
    Published
    21 July 2015

  5. Research recommendations

    effectiveness (beyond 24 weeks) of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate and placebo would be...